An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics
Pharmaceutics · 06.04.2023 · 15 (4) · 1158
DOI: 10.3390/pharmaceutics15041158 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 06.04.2023. Verfasst von Rahul G Ingle und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310027, China. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology, Ministry of Science and Technology of China.
Abstract (Originalsprache)
Nucleic acid (NA)-based biopharmaceuticals have emerged as promising therapeutic modalities. NA therapeutics are a diverse class of RNA and DNA and include antisense oligonucleotides, siRNA, miRNA, mRNA, small activating RNA, and gene therapies. Meanwhile, NA therapeutics have posed significant stability and delivery challenges and are expensive. This article discusses the challenges and opportunities for achieving stable formulations of NAs with novel drug delivery systems (DDSs). Here we review the current progress in the stability issues and the significance of novel DDSs associated with NA-based biopharmaceuticals, as well as mRNA vaccines. We also highlight the European Medicines Agency (EMA) and US Food and Drug Administration (FDA)-approved NA-based therapeutics with their formulation profiles. NA therapeutics could impact future markets if the remaining challenges and requirements are addressed. Regardless of the limited information available for NA therapeutics, reviewing and collating the relevant facts and figures generates a precious resource for formulation experts familiar with the NA therapeutics’ stability profile, their delivery challenges, and regulatory acceptance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310027, China.
- Dr. Rajendra Gode College of Pharmacy, Amravati 444602, India.
Förderung
- National Natural Science Foundation of China
- Ministry of Science and Technology
- Ministry of Science and Technology of China
Zitieren
APA
Ingle, R. G., & Fang, W. J. (2023). An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics. Pharmaceutics, 15(4), 1158. https://doi.org/10.3390/pharmaceutics15041158
Vancouver
Ingle RG, Fang WJ. An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics. Pharmaceutics. 2023;15(4):1158. doi:10.3390/pharmaceutics15041158
BibTeX
@article{Ingle2023,
author = {Ingle, Rahul G and Fang, Wei-Jie},
title = {An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {4},
pages = {1158},
doi = {10.3390/pharmaceutics15041158}
}
EUVIMED